Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring respons...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1583168/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|